Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2024 May Clinical trials Emicizumab prophylaxis is efficient and safe for infants with haemophilia A Read more
2024 April Health Innovation Long-term efficacy of etranacogene dezaparvovec in patients with severe haemophilia B Read more
2024 February Clinical trials Adding Isa to Kd improves outcomes in multiple myeloma, regardless of the time of relapse Read more
2024 January Health Innovation Oral decitabine–cedazuridine for myelodysplastic syndromes and chronic myelomonocytic leukae... Read more
2023 December Clinical trials Add-on therapy with danicopan improves haemoglobin levels in patients with PNH Read more
2023 November Clinical trials Emicizumab prophylaxis effectively prevents bleeding in patients with acquired haemophilia A Read more
Top
